What does a suppressed TSH of 0.24 µIU/mL with a normal free T4 of 1.55 ng/dL indicate, and what is the appropriate management?

Subclinical Hyperthyroidism Requiring Further Evaluation

Your TSH of 0.24 µIU/mL with normal FT4 of 1.55 ng/dL indicates subclinical hyperthyroidism, which requires repeat testing in 2-3 months to confirm persistence, followed by investigation of the underlying cause and risk stratification for cardiovascular and bone complications 1, 2.

What This Means

This laboratory pattern—suppressed TSH below the reference range (typically <0.4-0.45 mIU/L) with normal free thyroid hormones—defines subclinical hyperthyroidism 1, 2. However, a single abnormal TSH does not establish the diagnosis, as TSH can be transiently suppressed by various factors.

Immediate Next Steps

1. Repeat Testing in 2-3 Months

• Measure TSH, FT4, and add FT3 (free T3) to the panel
• Many patients with initially suppressed TSH will normalize spontaneously—approximately 45-54% of those with low TSH return to normal or detectable values within one year 3, 4
• Only persistent suppression warrants further investigation

2. Exclude Non-Thyroidal Causes Before Proceeding

Your TSH could be suppressed by factors other than thyroid disease:

• Recent or current illness (euthyroid sick syndrome) 1
• Medications: dopamine, glucocorticoids, dobutamine, or biotin supplements (causes false-low TSH in immunoassays) 1, 5
• First trimester pregnancy 1
• Recent treatment for hyperthyroidism (delayed TSH recovery) 1

Critical pitfall: Biotin supplementation is increasingly common and causes spuriously low TSH readings in most modern assays. Stop biotin for 2-3 days before retesting 5.

If TSH Remains Persistently Suppressed

Determine the Underlying Cause

Order the following tests:

• Thyroid peroxidase antibodies (TPO-Ab) and TSH receptor antibodies (TRAb) to identify Graves' disease
• Thyroid uptake and scan if antibodies are negative—will distinguish between:
  • Toxic nodular disease (hot nodules)
  • Thyroiditis (low uptake)
  • Graves' disease (diffuse increased uptake)

Risk Stratification

The decision to treat depends on your age and comorbidities, not just the TSH level. Subclinical hyperthyroidism carries increased risk of:

Cardiovascular complications 2:

• Atrial fibrillation (highest risk if age >65 years)
• Heart failure
• Increased mortality in those with pre-existing heart disease

Bone complications 2:

• Accelerated bone loss
• Increased fracture risk (especially postmenopausal women)

Cognitive effects 2:

• Some studies suggest increased risk of cognitive decline

Treatment Algorithm

Treat if ANY of the following apply:

• Age >65 years
• Pre-existing cardiovascular disease (especially atrial fibrillation risk)
• Osteoporosis or high fracture risk
• Symptomatic (tachycardia, tremor, heat intolerance, weight loss)
• TSH persistently <0.1 µIU/mL (undetectable carries higher risk than low-but-detectable values like yours) 3

Observation acceptable if:

• Age <65 years
• No cardiovascular or bone disease
• Asymptomatic
• TSH 0.1-0.4 µIU/mL (low but detectable)
• Close monitoring every 6-12 months

Important Nuances

The evidence shows that your specific TSH level of 0.24 µIU/mL (low but detectable) carries lower risk than undetectable TSH (<0.05-0.1 µIU/mL) 3. Research demonstrates that patients with detectable but suppressed TSH have similar rates of normalization as those with undetectable TSH, but the persistence of undetectable values and higher FT4 levels suggest greater thyroid hormone excess 3.

Note on FT4 interpretation: Your FT4 of 1.55 ng/dL likely sits in the upper-normal range. Studies show that even within the "normal" range, patients with subclinical hyperthyroidism tend to have FT4 in the high-normal territory, contrasting with low-normal FT4 seen in non-thyroidal illness 1, 4. This pattern supports true subclinical hyperthyroidism rather than assay interference or non-thyroidal illness.

Treatment Options (Once Cause Identified)

Depending on etiology:

• Radioactive iodine ablation (definitive for Graves' or toxic nodular disease)
• Antithyroid medications (methimazole preferred)
• Thyroid surgery (large goiters, nodules with concerning features)
• Radiofrequency ablation (selected cases)
• Observation with monitoring (low-risk patients)

The choice depends on the underlying cause, your age, comorbidities, and preferences 2.